search
Back to results

Bioequivalence Study (Candesartan 8 mg and Amlodipine 5 mg)

Primary Purpose

Hypertension

Status
Completed
Phase
Phase 1
Locations
Korea, Republic of
Study Type
Interventional
Intervention
CKD-330 8/5mg
Candesartan 8mg and Amlodipine 5mg
Sponsored by
Chong Kun Dang Pharmaceutical
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Hypertension

Eligibility Criteria

20 Years - 45 Years (Adult)MaleAccepts Healthy Volunteers

Inclusion Criteria:

  1. Healthy male volunteer in the age between 20 and 45 years old.
  2. Body weight ≥ 55 kg and Body weight in the range of calculated IBW ±20%.
  3. Subjects without a hereditary problems and chronic disease.
  4. Subjects whose clinical laboratory test values are inside the accepted normal range.
  5. Understand the requirements of the study and voluntarily consent to participate in the study.

Exclusion Criteria:

  1. Previous history or present of clinically significant hepatobiliary, nephrological, neurologic, respiratory, hemato-oncological, endocrine, urogenital, psychiatric, musculoskeletal, immune, otorhinolaryngological, cardiovascular system.
  2. History of gastrointestinal disease or gastrointestinal surgery to affect drug absorption.
  3. History of clinically significant allergies of amlodipine or candesartan or CCB or ARB or aspirin or antibiotic.
  4. Subjects with galactose intolerance.
  5. SBP ≥ 140 mmHg or< 90 mmHg, DBP ≥ 95 mmHg or < 60 mmHg, pulse ≥ 100 BPM.
  6. AST or ALT > 2*ULN, total bilirubin > 2*ULN
  7. Serum Creatinine > ULN
  8. Previous history or present of drug abuse.
  9. Subjects treated metabolizing enzyme inducers or inhibitors such as barbitals within 1 month prior to the first dosing.
  10. Subjects treated ethical drug or herbal medicine within 2 weeks, OTC or vitamin within 1 week prior to the first dosing.
  11. Subjects treated IP within 2 months prior to the first dosing.
  12. Subjects with whole blood donation within 2 months or component blood donation within 1 month or blood transfusion within 1 month prior to the first dosing.
  13. Alcohol > 21 units/week or cannot stop drinking.
  14. Cigarette > 10 cigarettes/day.
  15. Subjects with the plan dental treatment(extraction, orthodontic, nerve treatment) or any surgery(plastic surgery, eye surgery - LASIK, LASEK).
  16. Not eligible to participate for the study at the discretion of investigator.

Sites / Locations

  • Chungnam National University Hospital

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Experimental

Arm Label

Candesartan and Amlodipine

CKD-330

Arm Description

Candesartan 8mg and Amlodipine 5mg, PO, 1days or 22days

CKD-330 8/5mg, PO, 1days or 22days

Outcomes

Primary Outcome Measures

AUCt
A. Candesartan: 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 36, 48 hr B. Amlodipine: 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 36, 48, 72 hr
Cmax
A. Candesartan: 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 36, 48 hr B. Amlodipine: 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 36, 48, 72 hr

Secondary Outcome Measures

AUCinf
A. Candesartan: 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 36, 48 hr B. Amlodipine: 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 36, 48, 72 hr
tmax
A. Candesartan: 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 36, 48 hr B. Amlodipine: 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 36, 48, 72 hr
t1/2β
A. Candesartan: 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 36, 48 hr B. Amlodipine: 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 36, 48, 72 hr
CL/F
A. Candesartan: 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 36, 48 hr B. Amlodipine: 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 36, 48, 72 hr

Full Information

First Posted
July 2, 2014
Last Updated
November 27, 2014
Sponsor
Chong Kun Dang Pharmaceutical
search

1. Study Identification

Unique Protocol Identification Number
NCT02186496
Brief Title
Bioequivalence Study (Candesartan 8 mg and Amlodipine 5 mg)
Official Title
A Randomized, Open-label, Single-dosing, 2x2 Crossover Study to Compare the Safety and Pharmacokinetics of CKD-330 (Fixed-dose Combination of Candesartan 8 mg and Amlodipine 5 mg) With Coadministration of the Two Separate Drugs in Healthy Male Volunteers
Study Type
Interventional

2. Study Status

Record Verification Date
June 2014
Overall Recruitment Status
Completed
Study Start Date
July 2014 (undefined)
Primary Completion Date
August 2014 (Actual)
Study Completion Date
November 2014 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Chong Kun Dang Pharmaceutical

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The purpose of this study is to compare the safety and pharmacokinetics of CKD-330 (fixed-dose combination of Candesartan 8 mg and Amlodipine 5 mg) with coadministration of the two separate drugs in healthy male volunteers.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hypertension

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Crossover Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
32 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Candesartan and Amlodipine
Arm Type
Experimental
Arm Description
Candesartan 8mg and Amlodipine 5mg, PO, 1days or 22days
Arm Title
CKD-330
Arm Type
Experimental
Arm Description
CKD-330 8/5mg, PO, 1days or 22days
Intervention Type
Drug
Intervention Name(s)
CKD-330 8/5mg
Intervention Type
Drug
Intervention Name(s)
Candesartan 8mg and Amlodipine 5mg
Primary Outcome Measure Information:
Title
AUCt
Description
A. Candesartan: 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 36, 48 hr B. Amlodipine: 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 36, 48, 72 hr
Time Frame
0.5, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 36, 48, 72 hr
Title
Cmax
Description
A. Candesartan: 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 36, 48 hr B. Amlodipine: 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 36, 48, 72 hr
Time Frame
0.5, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 36, 48, 72 hr
Secondary Outcome Measure Information:
Title
AUCinf
Description
A. Candesartan: 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 36, 48 hr B. Amlodipine: 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 36, 48, 72 hr
Time Frame
0.5, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 36, 48, 72 hr
Title
tmax
Description
A. Candesartan: 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 36, 48 hr B. Amlodipine: 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 36, 48, 72 hr
Time Frame
0.5, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 36, 48, 72 hr
Title
t1/2β
Description
A. Candesartan: 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 36, 48 hr B. Amlodipine: 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 36, 48, 72 hr
Time Frame
0.5, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 36, 48, 72 hr
Title
CL/F
Description
A. Candesartan: 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 36, 48 hr B. Amlodipine: 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 36, 48, 72 hr
Time Frame
0.5, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 36, 48, 72 hr

10. Eligibility

Sex
Male
Minimum Age & Unit of Time
20 Years
Maximum Age & Unit of Time
45 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Healthy male volunteer in the age between 20 and 45 years old. Body weight ≥ 55 kg and Body weight in the range of calculated IBW ±20%. Subjects without a hereditary problems and chronic disease. Subjects whose clinical laboratory test values are inside the accepted normal range. Understand the requirements of the study and voluntarily consent to participate in the study. Exclusion Criteria: Previous history or present of clinically significant hepatobiliary, nephrological, neurologic, respiratory, hemato-oncological, endocrine, urogenital, psychiatric, musculoskeletal, immune, otorhinolaryngological, cardiovascular system. History of gastrointestinal disease or gastrointestinal surgery to affect drug absorption. History of clinically significant allergies of amlodipine or candesartan or CCB or ARB or aspirin or antibiotic. Subjects with galactose intolerance. SBP ≥ 140 mmHg or< 90 mmHg, DBP ≥ 95 mmHg or < 60 mmHg, pulse ≥ 100 BPM. AST or ALT > 2*ULN, total bilirubin > 2*ULN Serum Creatinine > ULN Previous history or present of drug abuse. Subjects treated metabolizing enzyme inducers or inhibitors such as barbitals within 1 month prior to the first dosing. Subjects treated ethical drug or herbal medicine within 2 weeks, OTC or vitamin within 1 week prior to the first dosing. Subjects treated IP within 2 months prior to the first dosing. Subjects with whole blood donation within 2 months or component blood donation within 1 month or blood transfusion within 1 month prior to the first dosing. Alcohol > 21 units/week or cannot stop drinking. Cigarette > 10 cigarettes/day. Subjects with the plan dental treatment(extraction, orthodontic, nerve treatment) or any surgery(plastic surgery, eye surgery - LASIK, LASEK). Not eligible to participate for the study at the discretion of investigator.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Jang Hee Hong
Organizational Affiliation
Chungnam National University Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Chungnam National University Hospital
City
Daejeon
State/Province
Chungcheongbuk-do
ZIP/Postal Code
301-721
Country
Korea, Republic of

12. IPD Sharing Statement

Learn more about this trial

Bioequivalence Study (Candesartan 8 mg and Amlodipine 5 mg)

We'll reach out to this number within 24 hrs